Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Zuo-Yan Zhang"'
Autor:
Yang-ling Li, Man-man Zhang, Lin-wen Wu, Ye-han Liu, Zuo-yan Zhang, Ling-hui Zeng, Neng-ming Lin, Chong Zhang
Publikováno v:
Journal of Biomedical Science, Vol 29, Iss 1, Pp 1-19 (2022)
Abstract Background Hepatocellular carcinoma (HCC) accounts for the majority of liver cancer cases, while metastasis is considered the leading cause of HCC-related death. However, the currently available treatment strategies for efficient suppression
Externí odkaz:
https://doaj.org/article/3e90ba0444124405bd834aefc6813435
Autor:
Xiang-yu Meng, Ke-jie Wang, Sha-zhou Ye, Jun-feng Chen, Zhao-yu Chen, Zuo-yan Zhang, Yi Li, Rui Yu, Qi Ma
Background Sinularin, a natural product that purified from soft coral, exhibits anti-tumor effects against various human cancers. However, the mechanisms are not well understood. Methods The inhibition of cell viability by Sinularin on human prostate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0bbfebebbf327dcbeeb301d85c951f1b
https://doi.org/10.21203/rs.3.rs-2091932/v1
https://doi.org/10.21203/rs.3.rs-2091932/v1
Publikováno v:
Oncogene. 39:6203-6217
Clear cell renal cell carcinoma (ccRCC) is the most common renal cancer and frequently diagnosed at an advanced stage. It is prone to develop unpredictable metastases even with proper treatment. Antiangiogenic therapy is the most effective medical tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f4d74126873ce059e87225b7188afe5
https://doi.org/10.1038/s41388-020-01428-3
https://doi.org/10.1038/s41388-020-01428-3
Autor:
Yang-ling Li, Shuang Xu, Dongmei Zhou, Lin-wen Wu, Chong Zhang, Ming-jun Rao, Neng-ming Lin, Zuo-yan Zhang
Publikováno v:
Cancer Biology & Medicine
Cancer Biology & Medicine, Vol 17, Iss 2, Pp 387-400 (2020)
Cancer Biology & Medicine, Vol 17, Iss 2, Pp 387-400 (2020)
Objective: Mcl-1 overexpression confers acquired resistance to Bcl-2 inhibitors in non-small cell lung cancer (NSCLC), but no direct Mcl-1 inhibitor is currently available for clinical use. Thus, novel therapeutic strategies are urgently needed to ta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f2438d347d1f0480f3aa989b9db0c50
https://doi.org/10.20892/j.issn.2095-3941.2019.0380
https://doi.org/10.20892/j.issn.2095-3941.2019.0380
Publikováno v:
OncoTargets and Therapy. 12:4585-4593
Purpose Pancreatic carcinoma is one of the most deadliest types of cancer, and relatively insensitive to the currently available chemotherapy. Thus, the discovery of novel therapeutic agents to prolong the survival times of patients with pancreatic c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::053093895b2312afaa2f7c908e671fbc
https://doi.org/10.2147/ott.s205097
https://doi.org/10.2147/ott.s205097
Autor:
Hua-jian Zhu, Dong-mei Zhou, Lin-wen Wu, Zuo-yan Zhang, Jian-kang Zhang, Neng-ming Lin, Chong Zhang
Publikováno v:
Biochemical and Biophysical Research Communications. 512:852-858
Regorafenib has been approved to treat patients who have HCC progression after sorafenib failure, however, regorafenib also faces the risk of drug resistance and subsequent progression of HCC patients. As LSD1 inhibitors can alleviate acquired resist
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::163f0b6f5410b561478cdaac348969dd
https://doi.org/10.1016/j.bbrc.2019.03.154
https://doi.org/10.1016/j.bbrc.2019.03.154
Autor:
Jiaan Shao, Shu-Min Dong, Ye-Han Liu, Huajian Zhu, Hua-Qing Liu, Linghui Zeng, Yang-ling Li, Chong Zhang, Man-Man Zhang, Jiankang Zhang, Zuo-Yan Zhang
Publikováno v:
Anti-Cancer Drugs.
Vinpocetine is widely used to treat cerebrovascular diseases. However, the effect of vinpocetine to treat hepatocellular carcinoma (HCC) has not been investigated. In this study, we revealed that vinpocetine was associated with antiproliferative acti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6039f0ed290e099cd82dac2ef003a6f
https://doi.org/10.1097/cad.0000000000001056
https://doi.org/10.1097/cad.0000000000001056
Autor:
Jiaan Shao, Huajian Zhu, Zuo-yan Zhang, Yang-ling Li, Lin-wen Wu, Neng-ming Lin, Jiankang Zhang, Linghui Zeng, Hui Chen, Chong Zhang, Xiu Hu
Publikováno v:
Phytomedicine : international journal of phytotherapy and phytopharmacology. 68
Background NSCLC is the major type of lung cancer and the survival rates of NSCLC patients remain low. AZD9291 is a third-generation EGFR-TKI and approved to treat NSCLC patients harboring EGFR T790M mutation and common targetable activating EGFR mut
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9797a3646454fc8ff927bd3e557ad252
https://pubmed.ncbi.nlm.nih.gov/32070867
https://pubmed.ncbi.nlm.nih.gov/32070867
Publikováno v:
OncoTargets and therapy
Purpose Pancreatic carcinoma is one of the most deadliest types of cancer, and relatively insensitive to the currently available chemotherapy. Thus, the discovery of novel therapeutic agents to prolong the survival times of patients with pancreatic c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::683905839466852a9e7cd08ba9f69822
https://pubmed.ncbi.nlm.nih.gov/31354292
https://pubmed.ncbi.nlm.nih.gov/31354292
Autor:
Zuo-yan Zhang, Shu-min Dong, Ye-han Liu, Man-man Zhang, Jian-kang Zhang, Hua-jian Zhu, Jia-an Shao, Hua-qing Liu, Yang-ling Li, Chong Zhang, Ling-hui Zeng
Publikováno v:
Anti-Cancer Drugs; Aug2021, Vol. 32 Issue 7, p727-733, 7p